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Abstract: Capsular devices for oral drug delivery were recently proposed and manufactured by 
injection molding (IM) as an evolution of traditional reservoir systems comprising a core and a 
functional coating. IM allowed the fabrication of capsule shells with release-controlling features 
based on the employed materials and the design characteristics. These features are independent of 
the drug, with significant savings in development time and costs. In previous work, IM was used to 
produce enteric-soluble capsules from blends of hydroxypropyl methylcellulose acetate succinate, 
with polyethylene glycol (PEG) as the plasticizer. In this work, the range of plasticizer 
concentrations and molar mass was broadened to evaluate in-depth how those parameters affect 
material processability and capsule performance over time. As expected, increasing the amount of 
the low molar mass plasticizer decreased the viscosity and modulus of the material. This simplified 
the molding process and enhanced the mechanical resistance of the shell, as observed during 
assembly. However, some samples turned out translucent, depending on several factors including 
storage conditions. This was attributed to plasticizer migration issues. Such results indicate that 
higher molar mass PEGs, while not significantly impacting on processability, lead to capsular 
devices with consistent performance in the investigated time lapse. 
Keywords: HPMCAS; PEG; plasticization; injection molding; drug delivery; gastric resistance; 
capsular device 
 
1. Introduction 
Over the last few years, injection molding (IM) has started to be employed in the pharmaceutical 
field, primarily at the research level for testing its feasibility in the manufacturing of drug products 
[1]. The possibility of producing either immediate-release (IR) dosage forms or drug delivery systems 
(DDSs) has been evaluated. DDSs are able to control the rate, time and/or site of drug release, 
fulfilling therapeutic needs that could not be met by IR products [2–8]. The rising interest towards 
the use of IM in DDS manufacturing derives from the intellectual property associated with the 
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resulting drug products, the flexibility in terms of design and composition, the reduction of both time 
and costs of production, and the possibility of avoiding the use of water as the solvent. Moreover, 
operating conditions, typically involving high pressure and temperature, could reduce microbial 
contamination on the one hand, and promote drug-polymer interactions on the other. This may lead 
to the formation of solid solutions increasing the dissolution rate of poorly soluble active ingredients. 
However, in order to avoid any degradation phenomena, processing temperatures need to be 
selected according to the thermal stability of the active molecules contained in the formulation. 
Recently, IM has been proposed to manufacture functional capsular containers, i.e., systems with 
innovative design, composition and performance characteristics intended to be filled with the active 
ingredient after molding [9–11]. Such containers would be suitable for conveying various drug 
formulations (e.g., powders, pellets, non-aqueous liquid preparations) and also for modifying the 
release of the drug. In this respect, they represent an evolution of traditional reservoir DDSs based 
on solid dosage form cores (e.g., tablets, gelatin capsules, granules) coated with a release-controlling 
polymeric barrier [12]. The coating layer would be replaced by the molded functional capsule shell, 
composed of a cap and body manufactured separately to be assembled after filling. The performance 
of such capsules depends on the shell composition and design features (e.g., morphology and 
thickness), irrespective of the specific characteristics of the formulation contained in the DDS. This 
may enable the independent development of inner formulation and container shell, which would 
offer major advantages in terms of time and cost to market. Using hydroxypropyl cellulose (HPC), 
capsular devices able to impart a lag phase prior to the release of their contents (Chronocap™) were 
successfully manufactured by IM. The possibility of modulating the duration of the lag phase by 
varying the thickness of the shell and its composition, mainly the molar mass of the HPC, was also 
demonstrated. This pointed out suitability of the Chronocap™ oral delivery platform for 
chronotherapy and for targeting the colonic region based on a time-dependent approach [9,10,13–16]. 
Furthermore, the prototyping ability of 3D printing versus IM was proved when manufacturing 
Chronocap™. 3D printing could speed up the screening of formulation and design development 
stages by overcoming the need for multiple molds and the revision of the entire molding process 
[17,18]. The feasibility of IM in the manufacturing of enteric-soluble capsular devices was also 
investigated using hydroxypropyl methylcellulose acetate succinate (HPMCAS), soluble at pH ≥ 5.5, 
plasticized with polyethylene glycol (PEG) [19]. Such devices were intended to remain intact in the 
acidic environment of the stomach and to release their contents into the small bowel due to the 
dissolution of the shell at the higher pH values of the intestine. The obtained capsules were shown to 
possess suitable physico-technological characteristics, and the desired release performance. 
To successfully apply IM in the manufacturing of drug products, the formulation step is 
especially challenging. It is essential to fulfill quality, efficacy and safety requirements for the final 
products. At the same time, the thermo-mechanical properties and rheological behavior of the 
components also have to be considered, in order to ensure proper moldability and stability over time. 
The research activities performed so far in the pharmaceutical field generally consist of feasibility 
studies. In these works, the main goals were the fabrication of prototypes by IM, and their 
characterization in terms of release performance. Only a few attempts to systematically evaluate the 
moldability of polymers approved for pharmaceutical use have been reported in the scientific 
literature [20,21]. In this respect, it was highlighted that the role of plasticizers is important to reduce 
the operating temperatures and decrease the risk of degradation. However, possible 
migration/leaching out of these additives has been widely reported in the case of food packaging and 
medical devices, and this problem has been associated with severe changes in the mechanical 
performance of end-products [22–24]. Notably, when dealing with drug products, such phenomena 
may affect not only the mechanical properties of the molded item but also its interaction with 
biological fluids, possibly affecting also its release behavior. A common strategy adopted in the 
plastics industry to limit migration of plasticizers and increase physical stability of molded products 
is the use of high molar mass plasticizing agents [25,26]. These agents are characterized by a lower 
diffusion rate in the polymer matrix, and are therefore more effectively retained in the molded 
product. However, their plasticizing efficiency may be reduced. 
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Based on these preliminary considerations, the aim of the present work is to systematically 
explore the effect of the addition of PEG plasticizers having different molar mass and concentration 
to HPMCAS, in order to investigate how these parameters affect the IM processability of the material 
and the performance of the resulting enteric-soluble capsular devices on an in-depth basis, also taking 
possible stability issues into account. 
2. Materials and Methods 
2.1. Materials 
Hydroxypropyl methylcellulose acetate succinate (HPMCAS, cellulose, 2-hydroxypropyl 
methyl ether, acetate, hydrogen butanedioate; AQUOT-LG®, Shin-Etsu, Tokyo, Japan) was employed 
as the main component of the gastroresistant capsule shells in view of its solubility at pH ≥ 5.5, its 
suitability for hot-processing and the experience acquired on similar IM processes [19,27,28]; 
polyethylene glycol (PEG; Clariant Masterbatches, Milan, Italy) was chosen as the plasticizer based 
on previous processing use, and PEG 1500 (PEG1.5; 1400–1600 g/mol), PEG 8000 (PEG8.0; 7300–9000 
g/mol) and PEG 20,000 (PEG20; 16,000–25,000 g/mol) were selected in order to evaluate the effect of 
the molar mass of the plasticizer. Acetaminophen (AAP, Rhodia, Milan, Italy) powder and the dye-
containing formulation Kollicoat IR® brilliant blue, based on a polyvinyl alcohol-polyethylene glycol 
graft-copolymer (BASF, Monza Brianza, Italy), were employed to fill the molded shells. AAP was 
then used to study the release performance of the DDSs, and the dye-containing formulations were 
used to visually check their opening. 
HPMCAS was kept in an oven at 40 °C for 24 h prior to use. Plasticized polymeric formulations 
were prepared by mixing HPMCAS powder with the selected plasticizer in a mortar (Table 1). The 
amount of PEG was expressed as % by weight (wt %) on the dry polymer. In order to investigate the 
effect of the amount of plasticizer, PEG1.5 was mixed with HPMCAS in 15 wt %, 25 wt % and 35 wt% 
proportions, corresponding to a mass fraction, Xmass, of 0.13, 0.2, and 0.26, respectively. The effect of 
the molar mass of the plasticizer was studied with the polymeric formulations containing 35 wt % of 
PEG, as this concentration was expected to provide the best processability. 
Table 1. Composition of the formulations investigated and relevant codes. 
 
PEG 
Formulation code 
Nominal molar mass Wt % 
HPMCAS 
- 0 0-PEG 
1500 
15 15-PEG1.5 
25 25-PEG1.5 
35 35-PEG1.5 
8000 35 35-PEG8.0 
20000 35 35-PEG20 
Polymeric formulations were directly loaded into the IM press without any further processing, 
minimizing the exposure to high temperatures and shear stresses. 
In order to produce samples for dynamic mechanical characterization, the same materials 
underwent hot melt extrusion in a counter-rotating twin-screw extruder (Haake™ MiniLab II 
microcompounder, Thermo Scientific, Milwaukee, WI, USA; screw diameter 5/14 and length 109.5 
mm) with a rectangular cross-section die (thickness 1 mm, width 4 mm). The extrusion temperature 
was set at 170 °C for unplasticized HPMCAS powder and 160 °C for all plasticized polymeric 
formulations; the screw speed was 60 rpm. 50 mm long bars were obtained by cutting the extrudates 
immediately after production. Some samples were kept at ambient conditions, others were kept at 40 
°C in an oven. Digital photographs (Nikon D70, Nikon, Tokyo, Japan) of the samples were also taken 
immediately after extrusion and at pre-determined time intervals. 
2.2. Methods 
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2.2.1. Rheological characterization of materials 
The flow behavior of the materials was investigated by measuring the pressure drop between 
two sensors located at the entrance and exit of a slit capillary die (width 10 mm, height 1.5 mm, length 
75 mm) integrated in the recirculation channel of the Haake™ MiniLab II microcompounder 
previously mentioned, equipped with two conical screws (in counter-rotating configuration). A 
protocol similar to that described by Casati F. et al. [21] was applied, and pressure drop and rotation 
speed data were processed as described by Yousfi et al. [29]. Tests were performed at temperatures 
between 170 °C and the minimum temperature allowed by the torque and pressure limitations of the 
extruder motor and pressure transducers, respectively. At least three tests were performed for each 
sample and temperature, and the average and standard deviation (sd) were calculated. 
2.2.2. Differential scanning calorimetry (DSC) 
DSC analyses were performed by DSC Q100 (TA Instruments, New Castle, DE, USA; n = 1), 
using nitrogen as a purge gas (70 mL/min). An empty aluminum pan was used as the reference 
standard. Samples of about 5 mg were heated in aluminum crucibles from −50 to 240 °C, maintained 
at this temperature for 1 min, cooled down to −50 °C and reheated up to 240 °C. Both heating and 
cooling steps were run at 10 °C/min. DSC experiments were carried out on unplasticized HPMCAS, 
plasticized polymeric formulations and specimens cut from extrudates at different times. 
2.2.3. Dynamic mechanical analysis (DMA) of extruded samples 
DMA was performed to assess the effect of the amount and molar mass of PEG on the 
mechanical behavior and glass transition of the considered material, and to investigate its stability 
over time and after thermal treatment. A TA RSA-III (TA Instruments, New Castle, DE, USA) 
dynamical mechanical analyzer was used to characterize samples extruded as described in the 
Materials section. Tests were performed immediately after extrusion and after 1, 3 and 10 days of 
treatment in an oven at Ttreatment = 40 °C. Further, samples kept in air and at room temperature were 
considered, as discussed in the Results section. 
The test protocol consisted in a temperature ramp of 3 °C/min from room temperature to the 
maximum temperature allowed by the sample before flowing. Tests were performed in tension, on 
bars with nominal gauge length, thickness and width of 20, 1.8 and 5 mm, respectively. To ensure 
linearity, measurements were carried out imposing a strain amplitude of 0.1% and at a 10 Hz 
frequency. To ensure that the sample was in tension throughout the whole test, a dynamic tracking 
algorithm allowed applying a static load 10% higher than the maximum dynamic load measured for 
any cycle. 
Figure 1 reports the temperature dependence of the conservative and dissipative components of 
the dynamic modulus, E’ and E’’ respectively, and of the loss factor, tan(δ)=E’’/E’. The glass transition 
temperature (Tg) is defined as the temperature at which tan(δ) reaches its maximum value. 
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Figure 1. 0-PEG. Temperature dependence of the conservative and dissipative components of the 
dynamic modulus, E’ and E’’, respectively, and of the loss factor, tan(δ) = E’’/E’. Tg is defined as the 
temperature at maximum of tan(δ) curve. 
2.2.4. IM of capsular devices 
IM processes were performed using a benchtop micro-molding press (BabyPlast 6/10P, 
Cronoplast S.L., Rambaldi S.r.l., Lecco, Italy) equipped with a mold composed of two interchangeable 
inserts for the manufacturing of the body and cap of capsular devices with constant nominal 
thickness of 600 µm [10]. The mold was characterized by the presence of a single cavity and entailed 
(i) a hot runner system to maintain the desired temperature during mold filling, preventing 
overheating in the upstream components of the IM machine, (ii) a length/diameter ratio of 1.5 to limit 
the flow path, (iii) a centered injection position to enable a balanced flow of the material in all 
directions, and (iv) a duct for injection of compressed air into the mold to ease ejection of the molded 
part. Each capsular device was composed by two parts – a body and a cap. The thickness of the wall 
of both parts was halved in the area where they overlapped to lock the device. This way, wall 
thickness was kept constant across the whole assembled device. 
Polymeric formulations were loaded into the IM press through a hopper. An amount of material 
(C) defined by the final position of the injecting plunger (ø = 10 mm) was then forced into a 
plasticating chamber containing heated spheres. The molten material then accumulated in the 
injection chamber. Both the injection and holding phases were performed in pressure control, with 
the injection pressure (P1) maintained for 2.5 s and the packing pressure (P2) maintained for 1.5 s. The 
constant pressure value was reached by moving the injection piston at selected rates (r1 and r2 for 
injection and holding, respectively); such rates are expressed as a percentage of the maximum rate 
achievable by the machine. The diameter of the injection nozzle was 1 mm. Four different 
temperatures (T1-T4) were set throughout the equipment, where the last one was the temperature of 
the hot runner of the molding system. The IM operating conditions for each material are reported in 
Table 2. 
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Table 2. IM operating conditions. 
Formulation T1 (°C) T2 (°C) T3 (°C) T4 (°C) C (mm) P1 (bar) r1 (%) P2 (bar) r2 (%) 
15-PEG1.5 130 135 155 165 6 30 0.4 20 0.3 
25-PEG1.5 130 135 150 160 6 30 0.4 20 0.3 
35-PEG1.5 130 135 150 160 7 30 0.4 20 0.3 
35-PEG8.0 130 135 160 170 6 30 0.4 20 0.3 
35-PEG20 130 135 160 170 6 30 0.4 20 0.3 
2.2.5. Characterization of capsular devices 
Bodies and caps were checked for weight (analytical balance BP211, Sartorius, Göttingen, 
Germany; n = 10) and thickness (MiniTest FH7200 equipped with FH4 probe, ø sphere = 1.5 mm, 
ElektroPhysik, Köln, Germany; n = 10). Digital photographs (Nikon D70, Nikon, Tokyo, Japan) were 
also taken (Figure 2). 
 
Figure 2. photographs of 25-PEG1.5-based body and cap (left) and assembled capsular device (right). 
Release performance - Capsule bodies were manually filled with approximately 80 mg of AAP 
(CV ≤ 2%) and then closed with matching caps. The compendial test for gastroresistant dosage forms 
(Dissolution Test for Delayed-Release Dosage Forms - Method B, USP38) was performed in apparatus 
2 (Dissolution System 2100B, Distek, North Brunswick Township, NJ, USA; n = 3) at 100 rpm and 37 
± 0.5 °C. The devices were maintained in hydrochloric acid buffer  pH 1.2 for 2 h, to simulate the 
gastric environment, and then transferred into phosphate buffer pH 6.8, to mimic the pH change after 
stomach emptying. Gastroresistant dosage forms are required to remain intact in the former stage of 
the test and release their drug content during the latter. Fluid samples were automatically withdrawn 
by a peristaltic pump every 5 min and the amount of drug released was assayed 
spectrophotometrically (cuvette with 1 mm optical path length; λ = 245 nm). Capsules were able to 
withstand the acidic medium (pH 1.2) for 2 h, whereas in the pH 6.8 buffer, there was a lag time prior 
to the break-up and release of the tracer. These results were in agreement with the behavior of 
traditional gastroresistant reservoir systems obtained by film coating and characterized by release-
controlling layers of hundred microns in thickness [30,31]. The in vitro lag time was expressed as the 
time required for 10% drug release in phosphate buffer (t10%). It was calculated by subtracting 120 
min (i.e., the time during which the devices were kept in pH 1.2 fluid) from the time obtained by 
linear interpolation of the experimental data immediately before and after this release percentage. By 
analogously calculating t90% and subtracting t10% from the resulting value, an index of the time needed 
for the complete release of the tracer was obtained (t90% - t10%). By way of example, the release profile 
of a 25-PEG1.5-based capsular device is reported in Figure 3. 
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Figure 3. release profile of a 25-PEG1.5-based capsular device; calculated t10% and t90% - t10% were about 
72 min and 7 min, respectively. 
Opening behavior - To investigate the opening mechanism of capsular devices, capsule body 
parts were manually filled with Kollicoat IR® brilliant blue and then closed with the matching caps. 
The filled capsules were immersed in unstirred pH 6.8 buffer at room temperature and digital 
photographs were taken at successive time points. 
3. Results and discussion 
3.1. Characterization of HPMCAS-based materials 
The rheological investigation was performed in order to assess the processability of HPMCAS, 
in a process temperature window limited by the need to avoid the degradation of the material that 
would impair its application to the manufacturing of drug products. During the development of 
industrial processes, it is necessary to assess the stability of the drug/materials and of the product, in 
order to rule out the formation of any hazardous degradation products and to ensure quality and 
safety [18]. 
Figure 4 shows the dependence of apparent shear viscosity on apparent shear rate for either 
unplasticized HPMCAS or HPMCAS containing different amounts of PEG1.5 as the plasticizer. In 
the case of unplasticized HPMCAS and 15-PEG1.5, it was possible to perform the test at 160 °C only, 
because at lower temperatures the maximum torque of the extruder was exceeded. For formulations 
containing higher amounts of plasticizer, it was possible to carry out the experiment at lower 
temperatures, and a master curve was built. The relevant shift factors, aT, showed an Arrhenius type 
dependence, Equation (1): 
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where Tref is the reference temperature, R the gas constant and E0 the viscous flow activation energy, 
≈184 kJ/mol for 25-PEG1.5 and ≈ 87 kJ/mol for 35-PEG1.5. The lower value of the activation energy in 
the second case may be attributed to the greater plasticization effect of the higher amount of PEG. In 
general, the values of E0 were significantly higher than those of common thermoplastic polymers, 
which are usually limited to few tens of kJ/mol and are always lower than 100 kJ/mol [32,33]. 
However, even higher values were observed for other cellulosic polymers by Baldi et al. [20], who 
explained their observation either with the presence of partially unmolten material or with partial 
degradation of the material during rather long tests at high temperature under shear. The same 
explanation may probably be adopted in the present case. 
Figure 4 reports also the fitting of data by Cross equation, Equation (2): 
  −   
   −   
=
1
1 + (  ̇) 
 (2) 
where λ is a time constant, m the power law index and η0 and η∞ the limiting viscosities at zero and 
infinite shear rates. The resulting fitting parameters are reported in Table 3. When computing the 
fitting parameters, η∞ was set equal to 0. 
 
Figure 4. steady-state apparent shear viscosity, ηapp, versus apparent shear rate at die wall,  ̇app,w , for 
0-PEG, 15-PEG1.5, 25-PEG1.5, 35-PEG1.5 from capillary rheometry tests at: 160 °C (), 155 °C (), 150 
°C (), 140 °C (). The reference temperature for 25-PEG1.5 and 35-PEG1.5 master curves is 160 °C. 
Lines represent the fitting with Cross equation (Equation (2)). 
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Table 3. fitting parameters of the Cross equation (Equation (2)) for unplasticized HPMCAS and its 
blends with different PEGs. 
Formulation η0 (Pa s) λ (s) m (–) R2 
0-PEG 5037 ± 389 0.071 ± 0.014 0.84 ± 0.04 0.998 
15-PEG1.5 1003 ± 55 0.050 ± 0.008 0.68 ± 0.01 0.994 
25-PEG1.5 236 ± 9 0.021 ± 0.003 0.55 ± 0.04 0.996 
35-PEG1.5 141 ± 17 0.019 ± 0.004 0.52 ± 0.02 0.995 
35-PEG8.0 115 ± 2 0.005 ± 0.003 0.71 ± 0.02 0.999 
35-PEG20 184 ± 14 0.019 ± 0.005 0.55 ± 0.04 0.998 
By comparing both the curves in Figure 4 and the zero shear viscosity, η0, in Table 3, the 
plasticizing effect of PEG is evident, as increasing the amount of plasticizer markedly reduces the 
viscosity, making the polymer easier to process. Therefore, the presence of a higher amount of the 
plasticizer should favor the processing of the material, as also confirmed by the torque needed to 
extrude the materials from the microcompounder, equal to 150, 110, 90, 40 N·cm for 0-PEG, 15-
PEG1.5, 25-PEG1.5 and 35-PEG1.5, respectively. 
The increase in the molar mass of PEG caused an increase in the apparent viscosity of 
formulations containing 35% of plasticizers, as reported in Figure 5. However, the impact of this 
parameter was limited if compared to that of the concentration of PEG at constant molar mass, and 
was expected to have a minor effect on the material processability. 
 
Figure 5. steady-state apparent shear viscosity, ηapp, versus apparent shear rate at die wall, γ̇   , at 
160 °C for 35-PEG1.5, 35-PEG8.0 and 35-PEG20. Lines represent the fitting with Cross equation 
(Equation (2)). 
The effects of plasticizers on the mechanical behavior of HPMCAS were further investigated 
through DMA. Figures 6 and 7 clearly show that the amount of plasticizer reduced the Tg and the 
modulus of the material at room temperature, respectively. 
The dependence of Tg on temperature could be effectively fitted using the Fox equation, 
Equation (3): 
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where χ1 is the PEG mass fraction, Tg2 is the unplasticized HPMCAS glass transition and Tg1 is the 
PEG glass transition. As the latter property was not available from experiments, it was left as a free 
fitting parameter, which had the value of  -38 °C, consistent with the value of −42 °C determined by 
DSC for the same material by Bochmann et al. [34]. 
 
Figure 6. Tg dependence on PEG mass fraction of HPMCAS-based formulations. Tests were 
performed immediately after sample production. The interpolation line uses the Fox equation 
(Equation (3)). 
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Figure 7. E’ dependence on PEG mass fraction of HPMCAS-PEG blends. Tests were performed 
immediately after sample production. The value was measured at 40 °C, during a temperature ramp 
experiment. 
The conservative component of the complex modulus (E’) seems to depend linearly on PEG 
weight fraction, at least in the considered range of compositions. The dependence is however stronger 
than could be expected from a simple rule of mixtures, and this is probably also due to the reduction 
of Tg induced by PEG. 
As for the effect of the molar mass of PEG, Figures 6 and 7 show that it is limited, as in the case 
of viscosity. 
Further, DMA allowed investigation of the stability of material properties over time. As reported 
in Figures 8 and 9, at increasing conditioning times at 40 °C, both Tg and the moduli increased, which 
can be related to the release of PEG from HPMCAS. This is particularly evident at higher PEG 
concentrations. The effect of molar mass is in this case marked: the increase in both Tg and E’ was 
higher for PEG8.0 and PEG1.5, and more limited for PEG20. 
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Figure 8. variation in Tg of plasticized HPMCAS samples after thermal treatment at 40 °C. Effect of 
concentration of PEG1.5 and of molar mass in the case of 35-PEG. 
 
Figure 9. variation in E’ of plasticized HPMCAS samples after thermal treatment at 40 °C. Effect of 
concentration of PEG1.5 and of molar mass in the case of 35-PEG. 
3.2. Manufacturing and characterization of HPMCAS-based capsular devices 
IM of capsule bodies and caps was successfully performed with all the formulations 
investigated, except for unplasticized HPMCAS (0-PEG). Common operating conditions (i.e., suitable 
to mold all the plasticized formulations) were employed in order to allow a better comparison of the 
capsular devices. The items obtained, appearing transparent, were characterized for weight and shell 
thickness. Figure 10 shows the thickness data measured from the thin and thick sections of PEG1.5-
based caps and bodies. The nominal thickness values are 300 µm (thin sections) and 600 µm (thick 
sections). Table 4 reports the weight data for the same formulations. 
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Figure 10. Average thickness values, with relevant sd, resulting from measurements performed on 
thin and thick sections of caps (a,b) and bodies (c,d) obtained from15-PEG1.5, 25-PEG1.5 and 35-
PEG1.5 formulations. 
Table 4. Average weight values, with relevant sd, resulting from measurements performed on caps 
and bodies obtained from 15-PEG1.5, 25-PEG1.5 and 35-PEG1.5 formulations. 
Formulation 
Weight (mg) 
Cap Body  
15-PEG1.5 114.57 (1.02)  125.79 (1.99) 
25-PEG1.5 115.46 (0.62)  128.07 (0.28) 
35-PEG1.5 115.85 (0.31)  127.51 (0.32) 
The weight data showed good reproducibility with all the tested formulations. On the other 
hand, the mismatch of measured versus nominal thickness values may be attributed to an 
overpacking during the holding phase of the IM process. This phenomenon might also explain the 
increase in thickness observed when the PEG content increases. The overpacking-related expansion 
is due to the difference in specific volume of the materials at the packing pressure at glass transition 
and at ejection conditions (typically room temperature and atmospheric pressure). The expansion 
increased with the absolute value of this difference. Since packing pressure was constant for all the 
molding experiments, and assuming that both the thermal expansion coefficient and the specific 
volume at ejection were independent of PEG concentration, the only difference among the various 
formulations could be related to the effect of PEG concentration on Tg that was previously reported. 
As PEG mass fraction increased, Tg was reduced: consequently, specific volume at glass transition 
decreased and the difference with specific volume at ejection increased. This caused a larger 
expansion of the capsule walls. 
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Capsule shells based on 15-PEG1.5 turned out to be too brittle, which was observed when filling 
them manually. Indeed, these capsules could not effectively be assembled without damaging the caps 
or breaking them up. Unplasticized HPMCAS and its 15% plasticized formulation were therefore 
discarded due to either unfeasible processing or poor mechanical resistance of the molded parts. 
All the capsular devices tested for interaction with aqueous fluids were able to resist in acidic 
medium irrespective of the amount and molar mass of the PEG employed and of the hydrodynamic 
conditions. In pH 6.8, the capsules were able to release their contents both in unstirred and stirred 
conditions (Figure 11, Table 5). Release occurred following dissolution of the polymeric barrier and 
final break-up of the shells, which took place some time after the pH change (lag time). The lag time 
was shown to be largely reduced under hydrodynamic conditions (≈60 min versus 4 h), as expected. 
Interestingly, it did not seem to be influenced by the type of plasticizer in the polymeric formulation, 
nor by its amount. Moving from 25% to 35% of PEG, despite the previously noted reduction in Tg, 
associated with an increase in HPMCAS free volume, no significant variation of t10% was observed. In 
the same way, the addition of PEG with higher molar mass to HPMCAS, which was already 
demonstrated to have a minor effect on the Tg, did not modify the release performance of the resulting 
capsular devices. Because of the lack of major changes in t10%, it could be hypothesized that an 
increased amount of plasticizer would make the dissolution and breaking up of the polymeric shell 
faster. This would counteract the effect of an increase in capsule thickness on the overall release 
performance. 
 
Figure 11. 25-PEG1.5 and 35-PEG1.5-based capsular devices filled with a dye-containing formulation 
at different time points during immersion in unstirred pH 6.8 buffer. Break-up was highlighted by 
the presence of blue coloration outside the shell after 260 min. 
Table 5. t10% and t90% - t10% (sd in brackets) relevant to capsular devices of different composition 
immediately after molding and after 30 days storage at 40 °C. 
Formulation 
t0 (min) t30days (min) 
t10%  t90% - t10% t10%  t90% - t10% 
25-PEG1.5 65.2 (6.1) 19.7 (11.9) 74.7 (6.4) 17.9 (8.1) 
35-PEG1.5 60.3 (5.4) 13.6 (8.4) 78.0 (4.3) 82.9 (15.4) 
35-PEG8.0 57.4 (7.1) 15.9 (6.1) 63.8 (5.7) 18.3 (8.4) 
35-PEG20 56.7 (15.1) 20.5 (3.0) 68.6 (24.6) 14.52 (4.8) 
Caps and bodies were stored at 40 °C for 30 days and then filled and assembled to evaluate the 
release performance of the capsular device over time. Samples based on the 35-PEG1.5 formulation 
lost their initial transparency and appeared translucent. This might be associated with the segregation 
of the plasticizer and its migration to the capsule surface. This phenomenon was accompanied by an 
increase of both the lag time and the release duration (t10% and t90% - t10% in Table 5). PEG migration in 
the capsule was in agreement with the DMA evidence of moduli and tan(δ) shift for samples prepared 
by hot melt extrusion and then conditioned in an oven at 40 °C, which pointed out the possible 
leaching of PEG from the polymeric barrier. The increase in lag time may be partly related to the 
same migration effect, which may have an impact on the release performance of the capsular devices 
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by leading to the presence of PEG-rich and PEG-depleted regions at the surface and in the bulk of the 
capsule wall, respectively. This would ultimately result in an overall reduction of the rate of water 
penetration into the polymeric barrier, also in turn reducing the dissolution rate. In this case, the 
polymeric network at the sample surface might be characterized by a higher concentration of 
hydrophilic/soluble plasticizer, improving water penetration rate, solvation of the polymer chains 
and final dissolution. However, the opposite situation should occur in the internal portion of the shell 
walls. 
3.3. Characterization of translucent HPMCAS-based samples 
A thermal and mechanical analysis was carried out in order to investigate the change in 
transparency of the capsular devices in time. The aim was verifying possible PEG 
segregation/migration and checking to which extent PEG molar mass may affect it. Due to the limited 
number of available capsular devices and the impossibility of retrieving samples suitable for 
mechanical testing out of them, the investigation was carried out on extruded specimens, which after 
extrusion were stored either at ambient conditions or in an oven at 40 °C. 
Visual inspection allowed to detect changes in the appearance both of samples stored at room 
temperature and at 40 °C. Interestingly, samples stored at room condition started getting translucent 
before than the samples stored at 40 °C. Furthermore, samples with different degrees of plasticization 
turned translucent at different times, in the 15-PEG1.5 ≈ 35-PEG8.0 > 25-PEG1.5 > 35-PEG20 > 35-
PEG1.5 order. 
Although no systematic study was carried out, DMA performed on translucent samples 
highlighted remarkable differences with respect to transparent ones. As an example, Figure 12 shows 
the results from 25-PEG1.5, after 50 days in an oven or at room temperature. 
 
Figure 12. Comparison between the dynamical mechanical responses of 25-PEG1.5 either maintained 
in an oven at 40 °C, indicated as “Transparent”, or at room temperature, indicated as “Translucent”. 
(a) Conservative component of the complex modulus, E’, versus temperature; (b) Loss factor, tan(δ) 
versus temperature. 
Furthermore, it was observed that only a thin external layer of the samples aged in air was 
translucent, while the core was still transparent. This suggested that the appearance of the samples 
would be due to PEG concentration at their surface. The oven treatment probably favors a 
homogeneous release of PEG and may be considered as a beneficial post-processing treatment for the 
DDS. 
To verify this hypothesis, DSC was employed to analyze material collected from aged samples 
and from completely transparent samples immediately after extrusion. In the first case, material was 
collected from both the thin external layer and the core. Figure 13 shows the thermogram for 35-
PEG1.5: a deep melting endotherm with a melting temperature, Tm, close to that of PEG 1500 (51 °C) 
can be observed only for the thin external layer. This seems to confirm the migration of PEG to the 
sample surface and its segregation. Similar endotherms were observed also for 25-PEG1.5, 35-PEG8.0 
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and 35-PEG20, with Tm close to the ones relevant to pure PEG (64 °C and 66 °C, respectively). 
However, in these cases the endothermic peaks were very small. 
 
Figure 13. Comparison between the DSC thermograms of dynamical mechanical responses of (a) a 
35-PEG1.5 extruded bar immediately after extrusion; (b) the inner, transparent region of a 35-PEG1.5 
bar maintained at room temperature for 2 months after extrusion; (c) the external thin opaque layer 
of a 35-PEG1.5 bar maintained at room temperature for 2 months after extrusion. 
From the specific melting enthalpies, ΔHmelting, measured in DSC for the layers and the pure 
PEGs, the PEG mass fraction, χPEG, on the external layer could be estimated as (Equation (4)): 
     =
Δ        ,          
Δ        ,   
 (4) 
in which ΔHmelting, thin layer and ΔHmelting, PEG are the specific melting enthalpies for the thin opaque layer 
taken form the sample and pure PEG. 
The results in Table 6 show that in the case of PEG1.5, a remarkable amount of PEG migrated to 
the surface. The amount is higher for HPMCAS loaded with the higher amount of PEG, suggesting a 
faster phenomenon in that case. On the other hand, migration at the same aging time was very limited 
in the case of 35-PEG8.0 and 35-PEG20: this would confirm the better suitability of higher molar mass 
PEGs as plasticizers for HPMCAS. However, a limited though still detectable migration was found 
even for the higher molar masses of PEG. This indicates that a longer investigation into stability 
should also be carried out at lower PEG concentrations. 
Table 6. Melting enthalpies and estimated PEG mass fraction in the thin opaque layers of 25-PEG1.5, 
35-PEG1.5, 35-PEG8.0 and 35-PEG20 bars maintained at room temperature for 2 months after 
extrusion. ΔHmelting, PEG is 146, 158 and 159 J/g for PEG1.5, PEG8.0 and PEG20, respectively. 
Formulation ΔHmelting, thin layer (J/g) χPEG (%) 
25-PEG1.5 5.0 3.4 
35-PEG1.5 22.4 15.2 
35-PEG8.0 0.3 0.3 
35-PEG20 0.3 0.3 
4. Conclusions 
Capsular devices suitable for filling after production with various drug-containing formulations 
to modify their release were recently described as an advantageous alternative to traditional coated 
reservoir systems. In this study, the feasibility of IM for manufacturing ready-to-use gastroresistant 
capsules was demonstrated starting from enteric-soluble HPMCAS. Considering the major role 
played by the plasticizer in the molding process and its impact on the mechanical as well as functional 
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characteristics of the molded capsules, a systematic study was performed to evaluate the outcome of 
the addition to HPMCAS of PEGs of different molar mass and in differing concentrations. 
The results obtained from rheological characterization showed that an increase in the amount of 
PEG markedly reduced the Tg of HPMCAS, and consequently reduced the viscosity of plasticized 
formulations. This made the IM process easier to carry out. The use of PEGs with higher molar mass 
was associated with a slightly increased apparent viscosity of the melt, but it did not result in major 
effects in terms of material processability. It was possible to successfully mold capsule bodies and 
caps with all the formulations investigated, plasticized with PEG 1500, 8000 and 20,000 in a 15–35 wt 
% concentration range. Items containing the lowest amount of PEG 1500 turned out to be too brittle 
to undergo the manual filling and assembly steps. On the other hand, the higher molar mass PEGs 
led to capsular devices with suitable physico-technological characteristics and consistent 
performance. 
A progressive loss of transparency was observed in the samples after a range of time periods, 
which was also affected by the storage conditions. This could be related to a migration of PEG within 
the polymer matrix over time, as supported by DSC analyses. Such a phenomenon, leading to 
concentration of plasticizer in the outer region of the molded products, was found to be especially 
evident in the presence of the lowest molar mass PEG at the highest concentration. These results were 
consistent with previous literature data relevant to applications of IM to areas other than the 
pharmaceutical one, e.g., for packaging purposes, where its use is more consolidated. The leaching 
of PEG, appearing faster on storage at 40 °C, was associated with an increase in Tg. However, it was 
not reflected in an alteration of the gastric resistance of the capsules. 
Although possible PEG migration issues did not seem to raise major concerns in the specific 
experimental settings here investigated, the data collected may recommend a curing treatment. This 
treatment, performed after molding the capsule bodies and caps, would be beneficial to improve the 
physical stability of ready-to-fill enteric-soluble capsular devices based on HPMCAS. 
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